| Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized … S Rögnvaldsson, TJ Love, S Thorsteinsdottir, ER Reed, JÞ Óskarsson, ... Blood Cancer Journal 11 (5), 94, 2021 | 65 | 2021 |
| Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study TE Long, OS Indridason, R Palsson, S Rognvaldsson, TJ Love, ... Blood Cancer Journal 12 (9), 133, 2022 | 36 | 2022 |
| Prevalence of smoldering multiple myeloma based on nationwide screening S Thorsteinsdóttir, GK Gíslason, T Aspelund, S Rögnvaldsson, ... Nature medicine 29 (2), 467-472, 2023 | 25 | 2023 |
| Screening for monoclonal gammopathy of undetermined significance: a population-based randomized clinical trial. First results from the Iceland Screens, Treats, or Prevents … SY Kristinsson, S Rögnvaldsson, S Thorsteinsdottir, ER Reed, ... Blood 138, 156, 2021 | 17 | 2021 |
| Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls S Rögnvaldsson, V Steingrímsson, I Turesson, M Björkholm, O Landgren, ... haematologica 105 (11), 2679, 2020 | 15 | 2020 |
| Prevalence of MGUS is high in the istopmm study but the prevalence of IgA MGUS does not increase with age in the way other immunoglobulin subtypes do TJ Love, S Rögnvaldsson, S Thorsteinsdottir, T Aspelund, ER Reed, ... Blood 140 (Supplement 1), 256-258, 2022 | 9 | 2022 |
| Prevalence of smoldering multiple myeloma: results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study S Thorsteinsdottir, GK Gislason, T Aspelund, S Rögnvaldsson, ... Blood 138 (Supplement 1), 151-151, 2021 | 8 | 2021 |
| Incidence and prognosis of patients with small intestinal neuroendocrine tumors in a population based nationwide study S Snorradottir, A Asgeirsdottir, S Rögnvaldsson, JG Jonasson, ... Cancer Epidemiology 79, 102197, 2022 | 7 | 2022 |
| Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study S Rognvaldsson, E Eythorsson, S Thorsteinsdottir, B Vidarsson, ... Blood Cancer Journal 11 (12), 191, 2021 | 7 | 2021 |
| A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre‐ibrutinib era V Steingrímsson, GK Gíslason, S Þorsteinsdóttir, S Rögnvaldsson, ... European journal of haematology 106 (3), 346-353, 2021 | 7 | 2021 |
| The first wave of COVID‐19 and concurrent social restrictions were not associated with a negative impact on mental health and psychiatric well‐being TJ Love, I Wessman, GK Gislason, S Rognvaldsson, S Thorsteinsdottir, ... Journal of Internal Medicine 291 (6), 837-848, 2022 | 5 | 2022 |
| Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls UA Shah, S Rögnvaldsson, A Derkach, M Björkholm, I Turesson, Y David, ... haematologica 107 (1), 284, 2022 | 5 | 2022 |
| Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized … S Rögnvaldsson, TJ Love, S Thorsteinsdottir, ER Reed, JÞ Óskarsson, ... | 5 | |
| Validity of chronic disease diagnoses in Icelandic healthcare registries S Rögnvaldsson, TE Long, S Thorsteinsdottir, TJ Love, SY Kristinsson Scandinavian Journal of Public Health 51 (2), 173-178, 2023 | 4 | 2023 |
| Autoimmune diseases are not associated with monoclonal gammopathy of undetermined significance: results of the prospective population-based Istopmm study IS Sverrisdottir, S Thorsteinsdóttir, S Rögnvaldsson, T Aspelund, ... Blood 140 (Supplement 1), 10031-10032, 2022 | 4 | 2022 |
| Defining new reference intervals for serum free light chains in individuals with reduced kidney function: results of the population-based on iceland screens treats or prevents … T Einarsson Long, OS Indridason, R Palsson, S Rögnvaldsson, TJ Love, ... Blood 138 (Supplement 1), 542-542, 2021 | 4 | 2021 |
| Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study AÝ Sigurbergsdóttir, S Rögnvaldsson, S Thorsteinsdóttir, I Sverrisdóttir, ... Haematologica 108 (12), 3392, 2023 | 3 | 2023 |
| Predicting the need for upfront bone marrow sampling in individuals with MGUS: derivation of a multivariable prediction model using the prospective population-based Istopmm cohort E Eythorsson, S Rögnvaldsson, S Thorsteinsdóttir, ER Reed, ... Blood 140 (Supplement 1), 266-267, 2022 | 3 | 2022 |
| Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population‐based cohort study S Rögnvaldsson, T Aspelund, S Thorsteinsdóttir, I Turesson, M Björkholm, ... European journal of haematology 107 (1), 137-144, 2021 | 3 | 2021 |
| Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study TE Long, S Rögnvaldsson, S Thorsteinsdottir, I Sverrisdottir, E Eythorsson, ... Blood 142, 535, 2023 | 2 | 2023 |
Sigurður Yngvi KristinssonFaculty of Medicine, University of Iceland and Department of Hematology, Landspitali NationalVerified email at hi.is
